Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Opsin Biotherapeutics
AddedFeb 19, 2024
UpdatedJun 18, 2026
Opsin Biotherapeutics

Opsin Biotherapeutics

Angel

Opsin Biotherapeutics: Pioneering opsin-based gene therapies for effective pain management.

HQ
Bedford, TX, US
Overview
Compare
Fundraising
Employees
Website

Opsin Biotherapeutics, founded with the mission to revolutionize pain management, focuses on developing opsin-based gene therapies. The company aims to provide alternatives to opioids and electrical spinal cord stimulators, addressing the chronic pain epidemic through optogenetic neuromodulation. Their innovative approach leverages advanced biotechnology to offer effective and sustainable pain relief solutions.

Notable figures in the company include leading experts in gene therapy and optogenetics. Opsin Biotherapeutics has garnered attention from prominent investors in the biotech sector, reflecting confidence in their groundbreaking technology. The company has achieved significant milestones in preclinical trials, demonstrating the potential of their therapies to transform chronic pain treatment and improve patient quality of life.

Opsin Biotherapeutics - Similar Companies

Opus Genetics logo

Opus Genetics

opusgtx.com

Genascence logo

Genascence

genascence.com

Nanoscope Therapeutics logo

Nanoscope Therapeutics

Oculogenex logo

Oculogenex

oculogenex.com

Navega Therapeutics logo

Navega Therapeutics

navegatx.com

Latigo Biotherapeutics logo

Latigo Biotherapeutics

latigobio.com

Opsidio logo

Opsidio

opsidio.com

NeuroTherapeutics Pharma logo

NeuroTherapeutics Pharma

Capsida Biotherapeutics logo

Capsida Biotherapeutics

capsida.com

Epic-Bio logo

Epic-Bio

epic-bio.com

Spine BioPharma logo

Spine BioPharma

spinebiopharma.com

Regel Therapeutics logo

Regel Therapeutics

Concentric Analgesics logo

Concentric Analgesics

RainBio logo

RainBio

rainbio.us

DiscGenics logo

DiscGenics

discgenics.com

Opsin Biotherapeutics - Quick Facts

Who are Opsin Biotherapeutics' competitors?

Companies similar to Opsin Biotherapeutics include Opus Genetics, Genascence, Nanoscope Therapeutics and Oculogenex.

Where is Opsin Biotherapeutics' headquarters located?

Opsin Biotherapeutics' headquarters is located in Bedford, TX, US.

When was Opsin Biotherapeutics' last funding round?

Opsin Biotherapeutics' most recent funding round was for $327.9k (USD) in July 2023.

How much has Opsin Biotherapeutics raised to-date?

As of Jul 27, 2023, Opsin Biotherapeutics has raised a total of $327.9k (USD).

How many employees does Opsin Biotherapeutics have?

Opsin Biotherapeutics has 1 employee as of Feb 4, 2024.

Opsin Biotherapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Gene Therapies
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified